Skip to main content

Advertisement

SpringerLink
Log in

HCV in liver transplantation

  • Review
  • Published:
Seminars in Immunopathology Aims and scope Submit manuscript

Abstract

HCV-related cirrhosis represents the leading indication for liver transplantation in the Western countries. HCV reinfection after liver transplantation occurs in virtually all patients transplanted for HCV-related liver disease Histological evidence of chronic HCV infection develops in 50 to 90 % of patients by 12 months after liver transplantation, and cirrhosis occurs in about 20 % of patients within 5 years after transplant. Several studies have evaluated host, viral, and transplant-related factors that might be associated with the severity of HCV recurrence. Among host factors, immunosuppression is one of the major factors that accounts for accelerated HCV recurrence and it has been an area of extensive research and controversy. Donor age, steatosis, and immunogenetic factors are also relevant in determining the outcome in patients transplanted for HCV-related cirrhosis. A major step to prevent complications of HCV recurrence related to the rapid fibrosis is the posttransplant antiviral treatment. Two strategies have been tried: pre-emptive or other strategies as soon as possible after liver transplantation or elective therapy once there is histological evidence of recurrent hepatitis C. Retransplantation due to graft failure from recurrent hepatitis C is rarely an option in the era of organ shortage as it is associated with poor outcome, but many case needs to be considered early in the evolution of disease. New antivirals may change the outcome dramatically of patients transplanted for HCV cirrhosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. National Health and Nutrition Examination Surveys 1988-2006. Available at: http://www.cdc.gov/nchs/about/major/nhanes. Accessed June 2008

  2. Kim WR (2002) The burden of hepatitis C in the United States. Hepatology 36:S30–34

    Article  PubMed  Google Scholar 

  3. Berenguer M, Lopez-Labrador FX, Wright TL (2001) Hepatitis C and liver transplantation. J Hepatol 35:666–678

    Article  PubMed  CAS  Google Scholar 

  4. Wiesner RH, Sorrell M, Villamil F (2003) Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 9:S1–9

    Article  PubMed  Google Scholar 

  5. Dragun J, Perez-Del-Pulgar S, Crespo G et al (2011) Characterization of the cross-neutralizing antibody response against hepatitis C virus in the liver transplantation setting. Am J Transplant 11:767–774

    Article  PubMed  CAS  Google Scholar 

  6. Garcia-Retortillo M, Forns X, Feliu A et al (2002) Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 35:680–687

    Article  PubMed  Google Scholar 

  7. Lyra AC, Fan X, Lang DM et al (2002) Evolution of hepatitis C viral quasispecies after liver transplantation. Gastroenterology 123:1485–1493

    Article  PubMed  Google Scholar 

  8. Ramirez S, Perez-Del-Pulgar S, Carrion JA et al (2009) Hepatitis C virus compartmentalization and infection recurrence after liver transplantation. Am J Transplant 9:1591–1601

    Article  PubMed  CAS  Google Scholar 

  9. Schvoerer E, Soulier E, Royer C et al (2007) Early evolution of hepatitis C virus (HCV) quasispecies after liver transplant for HCV-related disease. J Infect Dis 196:528–536

    Article  PubMed  Google Scholar 

  10. Saraf N, Fiel MI, Deboccardo G, Emre S, Schiano TD (2007) Rapidly progressive recurrent hepatitis C virus infection starting 9 days after liver transplantation. Liver Transpl 13:913–917

    Article  PubMed  Google Scholar 

  11. Guerrero RB, Batts KP, Burgart LJ et al (2000) Early detection of hepatitis C allograft reinfection after orthotopic liver transplantation: a molecular and histologic study. Mod Pathol 13:229–237

    Article  PubMed  CAS  Google Scholar 

  12. Wright TL, Donegan E, Hsu HH et al (1992) Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 103:317–322

    PubMed  CAS  Google Scholar 

  13. Gane EJ, Naoumov NV, Qian KP et al (1996) A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 110:167–177

    Article  PubMed  CAS  Google Scholar 

  14. Brown RS (2005) Hepatitis C and liver transplantation. Nature 436:973–978

    Article  PubMed  CAS  Google Scholar 

  15. Berenguer M, Prieto M, San Juan F et al (2002) Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 36:202–210

    Article  PubMed  Google Scholar 

  16. Firpi RJ, Abdelmalek MF, Soldevila-Pico C et al (2004) One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transpl 10:1240–1247

    Article  PubMed  Google Scholar 

  17. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR (2002) The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 122:889–896

    Article  PubMed  Google Scholar 

  18. Gane EJ, Portmann BC, Naoumov NV et al (1996) Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 334:815–820

    Article  PubMed  CAS  Google Scholar 

  19. Pelletier SJ, Iezzoni JC, Crabtree TD et al (2000) Prediction of liver allograft fibrosis after transplantation for hepatitis C virus: persistent elevation of serum transaminase levels versus necroinflammatory activity. Liver Transpl 6:44–53

    PubMed  CAS  Google Scholar 

  20. Prieto M, Berenguer M, Rayon JM et al (1999) High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 29:250–256

    Article  PubMed  CAS  Google Scholar 

  21. Sanchez-Fueyo A, Restrepo JC, Quinto L et al (2002) Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft. Transplantation 73:56–63

    Article  PubMed  Google Scholar 

  22. Yilmaz N, Shiffman ML, Stravitz RT et al (2007) A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation. Liver Transpl 13:975–983

    Article  PubMed  Google Scholar 

  23. Gane EJ (2008) The natural history of recurrent hepatitis C and what influences this. Liver Transpl 14(Suppl 2):S36–44

    Article  PubMed  Google Scholar 

  24. Baiocchi L, Angelico M, Petrolati A et al (2008) Correlation between liver fibrosis and inflammation in patients transplanted for HCV liver disease. Am J Transplant 8:673–678

    Article  PubMed  CAS  Google Scholar 

  25. Belli LS, Burroughs AK, Burra P et al (2007) Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study. Liver Transpl 13:733–740

    Article  PubMed  Google Scholar 

  26. Berenguer M, Ferrell L, Watson J et al (2000) HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 32:673–684

    Article  PubMed  CAS  Google Scholar 

  27. Neumann UP, Berg T, Bahra M et al (2004) Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 41:830–836

    Article  PubMed  CAS  Google Scholar 

  28. Sebagh M, Rifai K, Feray C et al (2003) All liver recipients benefit from the protocol 10-year liver biopsies. Hepatology 37:1293–1301

    Article  PubMed  Google Scholar 

  29. Wali MH, Heydtmann M, Harrison RF, Gunson BK, Mutimer DJ (2003) Outcome of liver transplantation for patients infected by hepatitis C, including those infected by genotype 4. Liver Transpl 9:796–804

    Article  PubMed  Google Scholar 

  30. Alter HJ, Seeff LB (2000) Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 20:17–35

    Article  PubMed  CAS  Google Scholar 

  31. Niederau C, Lange S, Heintges T et al (1998) Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 28:1687–1695

    Article  PubMed  CAS  Google Scholar 

  32. Poynard T, Bedossa P, Opolon P (1997) Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349:825–832

    Article  PubMed  CAS  Google Scholar 

  33. Berenguer M, Aguilera V, Prieto M et al (2003) Delayed onset of severe hepatitis C-related liver damage following liver transplantation: a matter of concern? Liver Transpl 9:1152–1158

    Article  PubMed  Google Scholar 

  34. McCaughan GW, Zekry A (2004) Mechanisms of HCV reinfection and allograft damage after liver transplantation. J Hepatol 40:368–374

    Article  PubMed  Google Scholar 

  35. Napoli J, Bishop GA, McGuinness PH, Painter DM, McCaughan GW (1996) Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology 24:759–765

    Article  PubMed  CAS  Google Scholar 

  36. Schirren CA, Jung M, Worzfeld T et al (2000) Cytokine profile of liver- and blood-derived nonspecific T cells after liver transplantation: T helper cells type 1/0 lymphokines dominate in recurrent hepatitis C virus infection and rejection. Liver Transpl 6:222–228

    PubMed  CAS  Google Scholar 

  37. Zekry A, Bishop GA, Bowen DG et al (2002) Intrahepatic cytokine profiles associated with posttransplantation hepatitis C virus-related liver injury. Liver Transpl 8:292–301

    Article  PubMed  Google Scholar 

  38. Kalambokis G, Manousou P, Samonakis D et al (2009) Clinical outcome of HCV-related graft cirrhosis and prognostic value of hepatic venous pressure gradient. Transpl Int 22:172–181

    Article  PubMed  Google Scholar 

  39. Gane E (2003) The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl 9:S28–34

    Article  PubMed  Google Scholar 

  40. Narang TK, Ahrens W, Russo MW (2010) Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria. Liver Transpl 16:1228–1235

    Article  PubMed  Google Scholar 

  41. Lai JC, Verna EC, Brown RS Jr et al (2011) Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men. Hepatology 54:418–424

    Article  PubMed  Google Scholar 

  42. Thuluvath PJ, Guidinger MK, Fung JJ et al (2010) Liver transplantation in the United States, 1999–2008. Am J Transplant 10:1003–1019

    Article  PubMed  CAS  Google Scholar 

  43. Foxton MR, Quaglia A, Muiesan P et al (2006) The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C. Am J Transplant 6:1922–1929

    Article  PubMed  CAS  Google Scholar 

  44. Veldt BJ, Poterucha JJ, Watt KD et al (2009) Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C. Am J Transplant 9:1406–1413

    Article  PubMed  CAS  Google Scholar 

  45. AlDosary AA, Ramji AS, Elliott TG et al (2002) Post-liver transplantation diabetes mellitus: an association with hepatitis C. Liver Transpl 8:356–361

    Article  PubMed  Google Scholar 

  46. Khalili M, Lim JW, Bass N et al (2004) New onset diabetes mellitus after liver transplantation: the critical role of hepatitis C infection. Liver Transpl 10:349–355

    Article  PubMed  Google Scholar 

  47. Brandman D, Pingitore A, Lai JC et al (2011) Hepatic steatosis at 1 year is an additional predictor of subsequent fibrosis severity in liver transplant recipients with recurrent hepatitis C virus. Liver Transpl 17:1380–1386

    Article  PubMed  Google Scholar 

  48. Reddy KR, Govindarajan S, Marcellin P et al (2008) Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin. J Viral Hepat 15:129–136

    PubMed  CAS  Google Scholar 

  49. Ge D, Fellay J, Thompson AJ et al (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399–401

    Article  PubMed  CAS  Google Scholar 

  50. Rauch A, Kutalik Z, Descombes P et al (2010) Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138:1338–1345, 1345 e1331-1337

    Article  PubMed  CAS  Google Scholar 

  51. Tanaka Y, Nishida N, Sugiyama M et al (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41:1105–1109

    Article  PubMed  CAS  Google Scholar 

  52. Charlton MR, Thompson A, Veldt BJ et al (2011) Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 53:317–324

    Article  PubMed  CAS  Google Scholar 

  53. Eurich D, Boas-Knoop S, Ruehl M et al (2011) Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation. Liver Transpl 17:289–298

    Article  PubMed  Google Scholar 

  54. Lange CM, Moradpour D, Doehring A et al (2011) Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. J Hepatol 55:322–327

    Article  PubMed  CAS  Google Scholar 

  55. Burak KW, Kremers WK, Batts KP et al (2002) Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 8:362–369

    Article  PubMed  Google Scholar 

  56. Berenguer M (2003) Host and donor risk factors before and after liver transplantation that impact HCV recurrence. Liver Transpl 9:S44–47

    Article  PubMed  Google Scholar 

  57. Berenguer M, Crippin J, Gish R et al (2003) A model to predict severe HCV-related disease following liver transplantation. Hepatology 38:34–41

    Article  PubMed  Google Scholar 

  58. Machicao VI, Bonatti H, Krishna M et al (2004) Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C. Transplantation 77:84–92

    Article  PubMed  Google Scholar 

  59. Wali M, Harrison RF, Gow PJ, Mutimer D (2002) Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 51:248–252

    Article  PubMed  CAS  Google Scholar 

  60. Mutimer DJ, Gunson B, Chen J et al (2006) Impact of donor age and year of transplantation on graft and patient survival following liver transplantation for hepatitis C virus. Transplantation 81:7–14

    Article  PubMed  Google Scholar 

  61. Briceno J, Ciria R, Pleguezuelo M et al (2009) Impact of donor graft steatosis on overall outcome and viral recurrence after liver transplantation for hepatitis C virus cirrhosis. Liver Transpl 15:37–48

    Article  PubMed  Google Scholar 

  62. Subramanian V, Seetharam AB, Vachharajani N et al (2011) Donor graft steatosis influences immunity to hepatitis C virus and allograft outcome after liver transplantation. Transplantation 92:1259–1268

    Article  PubMed  CAS  Google Scholar 

  63. Botha JF, Thompson E, Gilroy R et al (2007) Mild donor liver steatosis has no impact on hepatitis C virus fibrosis progression following liver transplantation. Liver Int 27:758–763

    Article  PubMed  Google Scholar 

  64. Burra P, Loreno M, Russo FP et al (2009) Donor livers with steatosis are safe to use in hepatitis C virus-positive recipients. Liver Transpl 15:619–628

    Article  PubMed  Google Scholar 

  65. Toniutto P, Fabris C, Bortolotti N et al (2004) Evaluation of donor hepatic iron concentration as a factor of early fibrotic progression after liver transplantation. J Hepatol 41:307–311

    Article  PubMed  CAS  Google Scholar 

  66. Belli LS, Burra P, Poli F et al (2006) HLA-DRB1 donor–recipient mismatch affects the outcome of hepatitis C disease recurrence after liver transplantation. Gastroenterology 130:695–702

    Article  PubMed  CAS  Google Scholar 

  67. Rosen HR, Hinrichs DJ, Gretch DR et al (1999) Association of multispecific CD4(+) response to hepatitis C and severity of recurrence after liver transplantation. Gastroenterology 117:926–932

    Article  PubMed  CAS  Google Scholar 

  68. Feray C, Caccamo L, Alexander GJ et al (1999) European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology 117:619–625

    Article  PubMed  CAS  Google Scholar 

  69. Feray C, Gigou M, Samuel D et al (1995) Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology 108:1088–1096

    Article  PubMed  CAS  Google Scholar 

  70. Ghobrial RM, Farmer DG, Baquerizo A et al (1999) Orthotopic liver transplantation for hepatitis C: outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience. Ann Surg 229:824–831, discussion 831-823

    Article  PubMed  CAS  Google Scholar 

  71. Zekry A, Whiting P, Crawford DH et al (2003) Liver transplantation for HCV-associated liver cirrhosis: predictors of outcomes in a population with significant genotype 3 and 4 distribution. Liver Transpl 9:339–347

    Article  PubMed  CAS  Google Scholar 

  72. Vargas HE, Laskus T, Wang LF et al (1998) The influence of hepatitis C virus genotypes on the outcome of liver transplantation. Liver Transplant Surg 4:22–27

    Article  CAS  Google Scholar 

  73. Di Martino V, Brenot C, Samuel D et al (2000) Influence of liver hepatitis C virus RNA and hepatitis C virus genotype on FAS-mediated apoptosis after liver transplantation for hepatitis C. Transplantation 70:1390–1396

    Article  PubMed  Google Scholar 

  74. Charlton M, Seaberg E, Wiesner R et al (1998) Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 28:823–830

    Article  PubMed  CAS  Google Scholar 

  75. Sreekumar R, Gonzalez-Koch A, Maor-Kendler Y et al (2000) Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology 32:1125–1130

    Article  PubMed  CAS  Google Scholar 

  76. Shackel NA, Jamias J, Rahman W et al (2009) Early high peak hepatitis C viral load levels independently predict hepatitis C-related liver failure post-liver transplantation. Liver Transpl 15:709–718

    Article  PubMed  Google Scholar 

  77. McCaughan GW, Shackel NA, Bertolino P, Bowen DG (2009) Molecular and cellular aspects of hepatitis C virus reinfection after liver transplantation: how the early phase impacts on outcomes. Transplantation 87:1105–1111

    Article  PubMed  CAS  Google Scholar 

  78. Feliu A, Gay E, Garcia-Retortillo M, Saiz JC, Forns X (2004) Evolution of hepatitis C virus quasispecies immediately following liver transplantation. Liver Transpl 10:1131–1139

    Article  PubMed  Google Scholar 

  79. Doughty AL, Painter DM, McCaughan GW (2000) Post-transplant quasispecies pattern remains stable over time in patients with recurrent cholestatic hepatitis due to hepatitis C virus. J Hepatol 32:126–134

    Article  PubMed  CAS  Google Scholar 

  80. Arenas JI, Gallegos-Orozco JF, Laskus T et al (2004) Hepatitis C virus quasi-species dynamics predict progression of fibrosis after liver transplantation. J Infect Dis 189:2037–2046

    Article  PubMed  Google Scholar 

  81. Massaguer A, Ramirez S, Carrion JA et al (2007) Evolution of the NS3 and NS5B regions of the hepatitis C virus during disease recurrence after liver transplantation. Am J Transplant 7:2172–2179

    Article  PubMed  CAS  Google Scholar 

  82. Humar A, Kumar D, Raboud J et al (2002) Interactions between cytomegalovirus, human herpesvirus-6, and the recurrence of hepatitis C after liver transplantation. Am J Transplant 2:461–466

    Article  PubMed  Google Scholar 

  83. Rosen HR, Chou S, Corless CL et al (1997) Cytomegalovirus viremia: risk factor for allograft cirrhosis after liver transplantation for hepatitis C. Transplantation 64:721–726

    Article  PubMed  CAS  Google Scholar 

  84. Manousou P, Samonakis D, Cholongitas E et al (2009) Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy. Liver Transpl 15:1783–1791

    Article  PubMed  Google Scholar 

  85. Humar A, Washburn K, Freeman R et al (2007) An assessment of interactions between hepatitis C virus and herpesvirus reactivation in liver transplant recipients using molecular surveillance. Liver Transpl 13:1422–1427

    Article  PubMed  Google Scholar 

  86. Nebbia G, Mattes FM, Cholongitas E et al (2007) Exploring the bidirectional interactions between human cytomegalovirus and hepatitis C virus replication after liver transplantation. Liver Transpl 13:130–135

    Article  PubMed  Google Scholar 

  87. Gaglio PJ, Malireddy S, Levitt BS et al (2003) Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors. Liver Transpl 9:1028–1035

    Article  PubMed  Google Scholar 

  88. Garcia-Retortillo M, Forns X, Llovet JM et al (2004) Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology 40:699–707

    Article  PubMed  Google Scholar 

  89. Thuluvath PJ, Yoo HY (2004) Graft and patient survival after adult live donor liver transplantation compared to a matched cohort who received a deceased donor transplantation. Liver Transpl 10:1263–1268

    Article  PubMed  Google Scholar 

  90. Guo L, Orrego M, Rodriguez-Luna H et al (2006) Living donor liver transplantation for hepatitis C-related cirrhosis: no difference in histological recurrence when compared to deceased donor liver transplantation recipients. Liver Transpl 12:560–565

    Article  PubMed  Google Scholar 

  91. Jain A, Singhal A, Kashyap R et al (2011) Comparative analysis of hepatitis C recurrence and fibrosis progression between deceased-donor and living-donor liver transplantation: 8-year longitudinal follow-up. Transplantation 92:453–460

    Article  PubMed  Google Scholar 

  92. Schmeding M, Neumann UP, Puhl G et al (2007) Hepatitis C recurrence and fibrosis progression are not increased after living donor liver transplantation: a single-center study of 289 patients. Liver Transpl 13:687–692

    Article  PubMed  Google Scholar 

  93. Shiffman ML, Stravitz RT, Contos MJ et al (2004) Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation. Liver Transpl 10:1248–1255

    Article  PubMed  Google Scholar 

  94. Taner CB, Bulatao IG, Keaveny AP et al (2011) Use of liver grafts from donation after cardiac death donors for recipients with hepatitis C virus. Liver Transpl 17:641–649

    Article  PubMed  Google Scholar 

  95. Samonakis DN, Germani G, Burroughs AK (2012) Immunosuppression and HCV recurrence after liver transplantation. J Hepatol 56(4):973–983

    Article  PubMed  CAS  Google Scholar 

  96. Berenguer M, Lopez-Labrador FX, Greenberg HB, Wright TL (2000) Hepatitis C virus and the host: an imbalance induced by immunosuppression? Hepatology 32:433–435

    Article  PubMed  CAS  Google Scholar 

  97. Berenguer M, Aguilera V, Prieto M et al (2006) Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J Hepatol 44:717–722

    Article  PubMed  CAS  Google Scholar 

  98. Samonakis DN, Triantos CK, Thalheimer U et al (2005) Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. Liver Transpl 11:386–395

    Article  PubMed  Google Scholar 

  99. Vivarelli M, Burra P, La Barba G et al (2007) Influence of steroids on HCV recurrence after liver transplantation: a prospective study. J Hepatol 47:793–798

    Article  PubMed  CAS  Google Scholar 

  100. Segev DL, Sozio SM, Shin EJ et al (2008) Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials. Liver Transpl 14:512–525

    Article  PubMed  Google Scholar 

  101. Samonakis DN, Mela M, Quaglia A et al (2006) Rejection rates in a randomised trial of tacrolimus monotherapy versus triple therapy in liver transplant recipients with hepatitis C virus cirrhosis. Transpl Infect Dis 8:3–12

    Article  PubMed  CAS  Google Scholar 

  102. Firpi RJ, Zhu H, Morelli G et al (2006) Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl 12:51–57

    Article  PubMed  Google Scholar 

  103. Goto K, Watashi K, Murata T et al (2006) Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811. Biochem Biophys Res Commun 343:879–884

    Article  PubMed  CAS  Google Scholar 

  104. Henry SD, Metselaar HJ, Lonsdale RC et al (2006) Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha. Gastroenterology 131:1452–1462

    Article  PubMed  CAS  Google Scholar 

  105. Ishii N, Watashi K, Hishiki T et al (2006) Diverse effects of cyclosporine on hepatitis C virus strain replication. J Virol 80:4510–4520

    Article  PubMed  CAS  Google Scholar 

  106. Nakagawa M, Sakamoto N, Enomoto N et al (2004) Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun 313:42–47

    Article  PubMed  CAS  Google Scholar 

  107. Paeshuyse J, Kaul A, De Clercq E et al (2006) The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology 43:761–770

    Article  PubMed  CAS  Google Scholar 

  108. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K (2003) Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 38:1282–1288

    Article  PubMed  CAS  Google Scholar 

  109. Cescon M, Grazi GL, Cucchetti A et al (2009) Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation. Liver Transpl 15:782–789

    Article  PubMed  Google Scholar 

  110. Selzner N, Renner EL, Selzner M et al (2009) Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation 88:1214–1221

    Article  PubMed  CAS  Google Scholar 

  111. Neyts J, Meerbach A, McKenna P, De Clercq E (1996) Use of the yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infections. Antivir Res 30:125–132

    Article  PubMed  CAS  Google Scholar 

  112. Firpi RJ, Nelson DR, Davis GL (2003) Lack of antiviral effect of a short course of mycophenolate mofetil in patients with chronic hepatitis C virus infection. Liver Transpl 9:57–61

    Article  PubMed  Google Scholar 

  113. Germani G, Pleguezuelo M, Villamil F et al (2009) Azathioprine in liver transplantation: a reevaluation of its use and a comparison with mycophenolate mofetil. Am J Transplant 9:1725–1731

    Article  PubMed  CAS  Google Scholar 

  114. Wiesner R, Rabkin J, Klintmalm G et al (2001) A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 7:442–450

    Article  PubMed  CAS  Google Scholar 

  115. Gurusamy KS, Tsochatzis E, Davidson BR, Burroughs AK (2010) Antiviral prophylactic intervention for chronic hepatitis C virus in patients undergoing liver transplantation. Cochrane Database Syst Rev CD006573

  116. Gurusamy KS, Tsochatzis E, Xirouchakis E, Burroughs AK, Davidson BR (2010) Antiviral therapy for recurrent liver graft infection with hepatitis C virus. Cochrane Database Syst Rev CD006803

  117. Charlton M, Bzowej N, Rossi S, Nelson D (2007) Prophylactic peginterferon alfa-2a/ribavirin vs no prophylaxis following orthotopic liver transplantation (OLT) for hepatitis C: 24-week virologic and safety responses. Hepatology 46:244A, Abstract

    Google Scholar 

  118. Roche B, Samuel D (2011) Is early antiviral therapy for recurrent hepatitis C after liver transplantation superior to later treatment? The answer is no. Liver Transpl 17:488–491

    Article  PubMed  Google Scholar 

  119. Guillouche P, Feray C (2011) Systematic review: anti-viral therapy of recurrent hepatitis C after liver transplantation. Aliment Pharmacol Ther 33:163–174

    Article  PubMed  CAS  Google Scholar 

  120. Carrion JA, Navasa M, Garcia-Retortillo M et al (2007) Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 132:1746–1756

    Article  PubMed  CAS  Google Scholar 

  121. Xirouchakis E, Triantos C, Manousou P et al (2008) Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies. J Viral Hepat 15:699–709

    Article  PubMed  CAS  Google Scholar 

  122. Garg V, van Heeswijk R, Lee JE et al (2011) Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 54:20–27

    Article  PubMed  CAS  Google Scholar 

  123. Fukuhara T, Taketomi A, Motomura T et al (2010) Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 139:1577–1585, 1585 e1571-1573

    Article  PubMed  CAS  Google Scholar 

  124. Charlton MR, Pockros PJ, Harrison SA (2006) Impact of obesity on treatment of chronic hepatitis C. Hepatology 43:1177–1186

    Article  PubMed  Google Scholar 

  125. Rao GA, Pandya PK (2011) Statin therapy improves sustained virologic response among diabetic patients with chronic hepatitis C. Gastroenterology 140:144–152

    Article  PubMed  CAS  Google Scholar 

  126. Cholongitas E, Theocharidou E, Goulis J et al (2012) Review article: extra skeletal effects of vitamin D in chronic hepatitis C infection. Aliment Pharmacol Ther 35(6):634–646

    Article  PubMed  CAS  Google Scholar 

  127. Petta S, Camma C, Scazzone C et al (2010) Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology 51:1158–1167

    Article  PubMed  CAS  Google Scholar 

  128. Carrion JA, Navasa M, Forns X (2010) Retransplantation in patients with hepatitis C recurrence after liver transplantation. J Hepatol 53:962–970

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Royal Free Sheila Sherlock Liver Centre and University Department of Surgery, Royal Free Hospital and UCL, Pond Street, NW3 2QG, London, UK

    Giacomo Germani, Emmanuel Tsochatzis, Vasilios Papastergiou & Andrew K Burroughs

  2. Department of Surgical, Oncological and Gastroenterological Sciences, Padua University Hospital, Padua, Italy

    Giacomo Germani

Authors
  1. Giacomo Germani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emmanuel Tsochatzis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vasilios Papastergiou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andrew K Burroughs
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew K Burroughs.

Additional information

This article is published as part of the special issue on immunopathology of viral hepatitis [34:4].

Rights and permissions

Reprints and permissions

About this article

Cite this article

Germani, G., Tsochatzis, E., Papastergiou, V. et al. HCV in liver transplantation. Semin Immunopathol 35, 101–110 (2013). https://doi.org/10.1007/s00281-012-0329-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00281-012-0329-5

Keywords

Search

Navigation